Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split

Aptevo Therapeutics Inc.

Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.
Company has 45 days (by July 7, 2025) to submit compliance plan; if accepted, until Nov 18, 2025 to regain compliance.
Announces 1-for-20 reverse stock split effective May 23, 2025; shares begin trading split-adjusted May 27.
Files prospectus supplement for up to $3.015M of common stock under ATM with Roth Capital.
Outstanding shares to reduce from ~13.5M to ~0.7M; no change to ticker APVO.

item 3.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.